UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004925
Receipt number R000005860
Scientific Title The efficacy and safety of direct renin inhibitor aliskiren on the blood glucose control of DPP-IV inhibitor
Date of disclosure of the study information 2011/02/01
Last modified on 2012/07/21 14:11:54

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The efficacy and safety of direct renin inhibitor aliskiren on the blood glucose control of DPP-IV inhibitor

Acronym

The efficacy and safety of direct renin inhibitor aliskiren on the blood glucose control of DPP-IV inhibitor

Scientific Title

The efficacy and safety of direct renin inhibitor aliskiren on the blood glucose control of DPP-IV inhibitor

Scientific Title:Acronym

The efficacy and safety of direct renin inhibitor aliskiren on the blood glucose control of DPP-IV inhibitor

Region

Japan


Condition

Condition

type 2 diabetes mellitus
hypertension

Classification by specialty

Endocrinology and Metabolism Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the efficacy and safety of direct renin inhibitor aliskiren on the blood glucose lowering effect of DPP-IV inhibitor in type 2 diabetic patients complicated with hypertension

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The value of HbA1c at the endopoitn of the trial

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

direct renin inhibitor aliskiren

Interventions/Control_2

amlodipine

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

70 years-old >

Gender

Male and Female

Key inclusion criteria

1. Patients who showed written informed consent to take part in this trial
2. Ptients who take ACE inhibitor or ARB for 3 months or longer
3. Ptients who take DPP-IV inhibitor for 3 months or longer
4. Patients whose HbA1c is between 5.8% and 7%
5. Patients who cannnot achieve the blood pressure treatment goal of 130/80 mmHg

Key exclusion criteria

1. type 1 diabetes mellitus
2. Patients who take both ACE inhibitor and ARB
3. Ptients who have allergy to the study drugs
4. Severe hypertension (180/110 mmHg or higher)
5. Pregnant women, women who want to be pregnant
6. Patients taking cyclosporine
7. Sever liver dysfunction (GOT>80 IU/L, GPT>80 IU/L), renal dysfunction (Cr>1.5(male), 1.4 (female) mg/dl)

Target sample size

70


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tanaka Masami

Organization

School of Medicine, Keio University

Division name

Department of Internal Medicine

Zip code


Address

35 Shinanomachi, Shinjuku-ku, Tokyo

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

School of Medicine, Keio University

Division name

Department of Internal Medicine

Zip code


Address


TEL


Homepage URL


Email



Sponsor or person

Institute

Department of Internal Medicine, School of Medicine, Keio University

Institute

Department

Personal name



Funding Source

Organization

Self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 02 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2010 Year 10 Month 06 Day

Date of IRB


Anticipated trial start date

2011 Year 02 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 01 Month 21 Day

Last modified on

2012 Year 07 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005860


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name